ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Patient reported outcomes"

  • Abstract Number: 0231 • ACR Convergence 2021

    Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool

    Jimmy Wiegel1, Bart Seppen1, Marieke ter wee2, Maarten Boers3, Michael Nurmohamed4 and wouter Bos5, 1Reade, Amsterdam, Netherlands, 2Amsterdam UMC, location VUmc, Amsterdam, Netherlands, 3Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 4Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, 5Reade Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The long-term and frequent evaluation of disease activity in patients with rheumatoid arthritis (RA) leads to a large burden of planned consultations at outpatient…
  • Abstract Number: 0481 • ACR Convergence 2021

    The Day-to-day Variability of Pain and the Relationship with Physical Activity in People with Knee Osteoarthritis: A Longitudinal, Observational Feasibility Study

    Arani Vivekanantham1, David Selby2, Mark Lunt2, Terence O’Neill2 and Will Dixon2, 1University of Oxford, Oxford, United Kingdom, 2University of Manchester, Manchester, United Kingdom

    Background/Purpose: Pain is a cardinal symptom in people with knee osteoarthritis (OA). However, pain in knee OA is often infrequently measured both in clinical practice…
  • Abstract Number: 0746 • ACR Convergence 2021

    Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?

    Patricia Katz1, Meera Subash1, Martin Bergman2 and Kaleb Michaud3, 1University of California San Francisco, San Francisco, CA, 2Martin Jan Bergman, MD, Ridley Park, PA, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Validated patient-reported outcome (PRO) measures play important roles in assessing and managing of patients with rheumatic diseases. However, use of these validated scales may…
  • Abstract Number: 0797 • ACR Convergence 2021

    Psychosocial Wellbeing and Illness Perceptions During the Early Disease Phase Predict Sustained Remission in Rheumatoid Arthritis

    Michal Doumen1, Diederik De Cock1, Sofia Pazmino1, Delphine Bertrand1, Rene Westhovens2 and Patrick Verschueren3, 1KU Leuven, Leuven, Belgium, 2University Hospitals KU Leuven, Maaseik, Belgium, 3University Hospitals Leuven - KULeuven, Leuven, Belgium

    Background/Purpose: Patient-reported outcomes (PROs) relating to global psychosocial wellbeing are rarely assessed in clinical trials for rheumatoid arthritis (RA), and specifically not to tailor additional…
  • Abstract Number: 1122 • ACR Convergence 2021

    Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities

    Jasvinder Singh, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Knee osteoarthritis (OA) has worse outcomes in racial/ethnic minorities. Yet, most of the qualitative studies include primarily Caucasian people with knee OA, with minimal…
  • Abstract Number: 1275 • ACR Convergence 2021

    Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study

    Line Uhrenholt1, Simone Høstgaard2, Julie Pedersen2, Robin Christensen3, Lene Dreyer1, Henrik Leffers4, Peter C Taylor5, Vibeke Strand6, Sren Jacobsen4, Anne Voss7, Jon Gregersen8 and Salome Kristensen1, 1Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, 3Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, 4Copenhagen Lupus and Vasculitis Clinic, Centre for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 5University of Oxford, Oxford, United Kingdom, 6Stanford University School of Medicine, Portola Valley, CA, 7Department of Rheumatology, Odense University Hospital, Odense C, Denmark, 8Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark, Aalborg, Denmark

    Background/Purpose: Patient-reported outcome measures (PROMs) provide the physician with an important insight into the patients’ perception of lupus disease activity. Technology and the widespread use…
  • Abstract Number: 1591 • ACR Convergence 2021

    Impact of the COVID-19 Pandemic and Lockdown on Wellbeing on Patients with Rheumatic Diseases. Results from the REUMAVID Study (Phase 1)

    Marco Garrido-Cumbrera1, Helena Marzo-Ortega2, Laura Christen3, José Correa-Fernández4, Sergio Sanz-Gomez4, Pedro Plazuelo-Ramos5, Laurent Grange6, Dale Webb7, Shantel Irwin8, Clare Jacklin9, Souzi Makri10, Elsa Frazão Mateus11, Serena Mingolla12, Katy Antonopoulou13 and Victoria Navarro-Compán14, 1Health & Territory Research (HTR), University of Seville, Sevilla, Spain, 2NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, 3Novartis Pharma AG, Basel, Switzerland, 4Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, 5Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, 6French League Against Rheumatism (AFLAR), Echirolles, France, 7National Axial Spondyloarthritis Society (NASS), London, United Kingdom, 8Arthritis Action, London, United Kingdom, 9National Rheumatoid Arthritis Society (NRAS), London, United Kingdom, 10Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, 11Liga Portuguesa Contra as Doenças Reumáticas (LPCDR), Lisbon, Portugal, 12Italian National Association of People with Rheumatic and Rare Diseases (APMARR), Bari, Italy, 13Hellenic League Againts Rheumatism (ELEANA), Athens, Greece, 14Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain

    Background/Purpose: The COVID-19 pandemic has impacted wellbeing of patients with Rheumatic and Musculoskeletal Diseases (RMDs). The aim is to assess wellbeing its associated factors in…
  • Abstract Number: 1779 • ACR Convergence 2021

    A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)

    Nancy Shadick1, Kumiko Schnock2, Vivi Feather2, Jing Cui3, Gabriela Maica2, Alexa Marshall2, Wynona Francis2, Muibat Yussuff2, Lourdes Maria Perez Chada2, Michael E. Weinblatt2 and Joseph Merola4, 1Brigham & Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham Women's Hospital, Boston, MA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
  • Abstract Number: 0234 • ACR Convergence 2021

    Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial

    Louis Bessette1, Beatriz Joven-Ibáñez2, Carlo Selmi3, Naijun Chen4, Koji Kato5, Ralph Lippe6, Patrick Zueger7, Jayeshkumar Patel4 and Joseph Merola8, 1Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 2University Hospital 12 de Octubre, Madrid, Spain, 3Humanitas Research Hospital and Humanitas University, Milan, Italy, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc, Shinagawa- Ku, Japan, 6AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, 7AbbVie Inc., Mettawa, IL, 8Harvard Medical School, Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: Pain is a dominant feature of PsA and has been identified by the GRAPPA-OMERACT working group as a core disease domain. Its control is…
  • Abstract Number: 0499 • ACR Convergence 2021

    Preliminary Assessment of Internal Reliability and Construct Validity of Long and Short-form Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaires

    John Pauling1, Lan Yu2, Christopher Denton3, Tracy Frech4, Ariane Herrick5, Laura Hummers6, Lesley Ann Saketkoo7, Ami Shah8, Dinesh Khanna9 and Robyn Domsic2, 1Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2University of Pittsburgh, Pittsburgh, PA, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 4University of Utah, Salt Lake City, UT, 5University of Manchester, Salford, United Kingdom, 6Johns Hopkins Univerisity, Baltimore, MD, 7University Medical Center - Comprehensive Pulmonary Hypertension Center, New Orleans, LA, 8Johns Hopkins Rheumatology, Baltimore, MD, 9University of Michigan, Ann Arbor, MI

    Background/Purpose: The Assessment of Systemic sclerosis-associated RAynaud’s Phenomenon (ASRAP) questionnaire is a novel patient-reported outcome instrument devised to assess the severity and impact of SSc-RP.…
  • Abstract Number: 0748 • ACR Convergence 2021

    Performance of Standardized Scores for Disease Assessment and Pain in Patients Withspondyloarthritis and Fibromyalgia

    Xenofon Baraliakos, Styliani Tsiami, Maria Claudia Gkelaki, Piet Dukatz, Uta Kiltz and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: The pathogenesis of spondyloarthritis (SpA) including axial SpA (axSpA) and psoriatic arthritis (PsA) differs from fibromyalgia (FM). However, symptoms partially overlap and both patient…
  • Abstract Number: 0798 • ACR Convergence 2021

    The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)

    Lillian-Ruiheng Chen1, Orit Schieir2, Marie-France Valois3, Janet Pope4, Susan Bartlett3, Gilles Boire5, Glen Hazlewood6, Carol Hitchon7, Edward C. Keystone8, Diane Tin9, Carter Thorne10, Narcisse Singbo1, Vivian Bykerk11 and Louis Bessette12, 1Centre de recherche du CHU de Québec-Université Laval, Québec City, QC, Canada, 2Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 3McGill University, Montréal, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Universite de Sherbrooke, Sherbrooke, QC, Canada, 6University of Calgary, Calgary, AB, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9The Arthritis Program Research Group, Newmarket, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11Hospital for Special Surgery, New York, NY, 12Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada

    Background/Purpose: Comorbid conditions have been shown to negatively influence the achievement of treatment targets in rheumatoid arthritis (RA) patients. The comorbid conditions may bias the…
  • Abstract Number: 1130 • ACR Convergence 2021

    Osteoarthritis Patients Feel Their Tissue Remodeling

    Anne-Christine Bay-Jensen1, Yi He2, Christian Thudium1 and Morten Karsdal3, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience A/S, Herlev, Denmark, 3Nordic Bioscience, Herlev

    Background/Purpose: Osteoarthritis (OA) is a chronic disease characterized by pain and disability. Central to the revised FDA guidelines for the approval of a disease modifying…
  • Abstract Number: 1279 • ACR Convergence 2021

    Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort

    Romina Nieto1, Eduardo Ferreira Borba2, Eugenia Settecasse3, Diana Fernandez-Avila4, Laura Maurelli5, Carla Gobbi6, Verónica Saurit7, Fernando Arizpe8, Julieta Daniele9, Maria Constanza Bertolaccini10, Eduardo Kerzberg11, María de los Ángeles Gargiulo12, Anabella Rodriguez13, Ana Carolina Londe14, Vitalina Sousa Barbosa15, Andrese Aline Gasparin16, Carolina Albanez A Cunha Andrade17, Luciana Parente Costa Seguro18, Lucas Victoria de Oliveira Martins19, Oscar Neira20, Carolina Llanos21, Loreto Massardo22, Antonio Iglesias23, Ivana Nieto Aristizábal24, Gloria Vasquez25, Paul Mendez-Patarroyo26, Lizeth de la Hoz Rueda23, José Martínez Pérez27, Reyna Sánchez Briones28, Mario Pérez Cristóbal29, Eduardo Martin-Nares30, Yaneli Juárez-Vicuña31, Yelitza Gonzalez Bello32, Jorge González García33, Dionicio Galarza-Delgado34, Marcos Vázquez35, Patricia Langjarh35, Magaly Alva Linares36, Cristina Reategui-Sokolova37, Armando Calvo Quirós38, Edral Rodriguez39, Ricardo Robaina40, Martín Rebella41, Graciela Alarcn42, Ashley Orillion43, Chetan Karyekar44, Federico Zazzetti45 and Guillermo Pons-Estel46, 1Hospital Provincial de Rosario, Rosario, Argentina, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 3Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, 6Hospital Córdoba, Córdoba, Argentina, 7Hospital Privado Universitario de Córdoba, Córdoba, 8Hospital HIGA San Martín, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, 10Hospital Padilla, San Miguel de Tucumán, Argentina, 11Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, 12Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, 13CEMIC, Buenos Aires, Argentina, 14Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, 15Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, 16Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 17Universidad Federal de Pernambuco, Recife, Brazil, 18Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, 19Universidad Federal São Paulo, São Paulo, Brazil, 20Hospital del Salvador, Santiago, Chile, 21Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, 22Universidad San Sebastián, Santiago, Chile, 23Clínica de la Costa Ltda., Barranquilla, Colombia, 24Fundación Valle del Lili, Cali, Colombia, 25Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, 26Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, 27Hospital Luis Vernaza, Guayaquil, Ecuador, 28Centro Médico La Raza, Ciudad de México, Mexico, 29Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, 30Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 31Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 32Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, 33Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, 34Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, 35Hospital de Clínicas I, Asunción, Paraguay, 36Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 37Hospital Guillermo Almenara Irigoyen, Lima, Peru, 38Hospital Cayetano Heredia, Lima, Peru, 39Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, 40Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 41Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 42University of Alabama at Birmingham, Birmingham, AL, 43Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, 44Janssen R&D, Spring House, PA, 45Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, 46Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina

    Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life…
  • Abstract Number: 1592 • ACR Convergence 2021

    ACT for Lupus: Pilot Study of a Novel Acceptance and Commitment Therapy (ACT) Online Program to Support Patients with Lupus During the COVID-19 Pandemic

    Tessa Englund1, Saira Sheikh2, Becki Cleveland1, Emily McCormick1, Crystal Schiller3 and Teresa Dickson1, 1Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 2University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, 3University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease associated with significant symptom burden, including fatigue, anxiety, depression, pain, and negative impacts on health-related quality…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • …
  • 43
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology